Health Care Stakeholders Seek Withdrawal Of Part D Proposed Rule
This article was originally published in The Pink Sheet Daily
The wide-ranging and lengthy Medicare Part D proposal issued in January includes provisions that have sparked serious concern from a diverse array of advocates, causing them to come together to write CMS Administrator Tavenner asking for its withdrawal.
You may also be interested in...
CMS estimates that removing antidepressants, antipsychotics and immunosuppressants from “protected class” status in Medicare Part D could save $720 million between 2016 and 2019.
Former senior advisor to President Trump warns that failure to reform drug pricing practices has seriously handicapped prospects for reimbursing cell and gene therapy under existing US payer programs.
Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’